The Institute for Safe Medication Practices released its 1997 list of "cheers and jeers." Based in Warminster, PA, the non-profit organization serves as an education resource for medication-system errors. Its cheers and jeers, some of which are excerpted below, are issued as part of an effort to improve drug distribution, naming, packaging, labeling and delivery-system design.
The Institute for Safe Medication Practices released its 1997 list of "cheers and jeers." Based in Warminster, PA, the non-profit organization serves as an education resource for medication-system errors. Its cheers and jeers, some of which are excerpted below, are issued as part of an effort to improve drug distribution, naming, packaging, labeling and delivery-system design.
CHEERS to pharmaceutical companies who responded to product labeling, packaging, nomenclature and design problems. Amgen, Baxa Corp., Bristol-Myers Squibb and Marsam, for example, made strides in correcting or improving-medication error prevention.
JEERS to companies who have not responded to serious medication safety concerns. Especially jeer-worthy is the practice of extending product-line names to new products that do not contain the same drugs. This confuses practitioners and consumers, according to the Institute of Safe Medical Practices.
CHEERS to the Food and Drug Administration for requiring products that contain 30 mg or more of iron per unit to be packaged as individual doses.
JEERS to the Food and Drug Administration and manufacturers for allowing the products' identities to be replaced by iron-related warnings on each package. This could slow emergency room personnel who need to identify what product was taken in accidental poisoning situations, and it requires pharmacies to repackage the product for use in institutions.
CHEERS to companies that obtain practitioner input on potential safety problems with labeling, packaging and nomenclature prior to product launch.
CHEERS to companies that provide clear and accurate resource materials and advertisements. Bristol-Myers Squibb, for example, voluntarily changed the "u" in its Blenoxane® advertisements to "units" to prevent possible errors, the Institute of Safe Medical Practices noted.
CHEERS to the many practitioners who reported adverse drug events to their institutions-the Food and Drug Administration and the Institute of Safe Medical Practices-in 1997. Better reporting behavior reduces the likelihood that such errors happen again. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.